More coming from the Lee partnership!
"Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, stated, “We at Sorrento are happy with the collaboration with our colleagues at Lee’s Pharma and are satisfied with the clinical advance of our first therapeutic antibody partnership in socazolimab. We currently plan to expand our partnership with Lee’s Pharma and are in discussions regarding the co-development of additional therapeutic antibodies from Sorrento to treat hematologic and solid tumors.”
The anti-PD-L1 is obviously another blockbuster drug. It can bring in hundreds of millions of upfront, milestone and royalty payments. Or simply be sold off for billions to finance the rest of the cancer pipline eg. ADNAB, DAR-T and plasmid DNA!